In patients with type 2 diabetes
with high CV risk
with high CV risk
CV DEATH HAS A
NEW OPPONENT
Jardiance® (Empagliflozin) is the only type 2 diabetes pill proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease
EMPA-REG Outcome Trial Results
Document ID: VV_103548
06/12/2018
Author: Boehringer Ingelheim
Demonstrating cardioprotection with jardiance by reducing the risk of CV death on top of standard of care
123,000
Views
100k 340
RElated content
Production date: Dec 2018